Stephen Thomas Keir | Scholars@Duke

Stephen Thomas Keir
Professor in Neurosurgery

Current Appointments & Affiliations

Professor in Neurosurgery, Neurosurgery, Neuro-Oncology, Neurosurgery 2017
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1992

Contact Information

231 Baker House, Durham, NC 27710
Box 3624 Med Ctr, Durham, NC 27710
keir0001@mc.duke.edu (919) 684-5301

Background
Education, Training, & Certifications
- DrPH, University of North Carolina at Chapel Hill 2004
- M.P.H., University of North Carolina at Chapel Hill 2001
Duke Appointment History
- Professor in Neurosurgery, Neurosurgery, Neurosurgery 2015 - 2017
- Associate Professor of Surgery, Neurosurgery, Neurosurgery 2010 - 2015
- Associate Professor in Surgery, Neurosurgery, Neuro-Oncology, Neurosurgery 2009 - 2010
- Assistant Professor in Surgery, Neurosurgery, Neuro-Oncology, Neurosurgery 2006 - 2008
- Assistant Research Professor in Surgery, Neurosurgery, Neuro-Oncology, Neurosurgery 2005 - 2006
Research
Selected Grants
- Assessment of ST101 in Glioblastoma awarded by Sapience Therapeutics Inc. 2018 - 2020
- Evaluation of Panobinostat in Patient Derived Adult IDH1 Mutated Brain Tumor Xenografts awarded by Midatech Pharma Plc 2018 - 2019
- Pediatric Brain Tumor Consortium awarded by St. Jude Children's Research Hospital 2014 - 2017
- Truncated GLI1 In Glioblastoma awarded by National Institutes of Health 2014
- Regional AGT Depletion of CNS and Leptomeningeal Tumors awarded by National Institutes of Health 2002 - 2006
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Thompson, EM, Landi, D, Ashley, D, Keir, ST, and Bigner, D. "Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status." Journal of Neuro Oncology 140, no. 2 (November 2018): 261-268. Full Text
  - Poteet, E, Choudhury, GR, Winters, A, Li, W, Ryou, M-G, Liu, R, Tang, L, Ghorpade, A, Wen, Y, Yuan, F, Keir, ST, Yan, H, Bigner, DD, Simpkins, JW, and Yang, S-H. "Correction: Reversing the Warburg effect as a treatment for glioblastoma." The Journal of Biological Chemistry 293, no. 39 (September 2018): 14973-null. Full Text
  - Gedeon, PC, Schaller, TH, Chitneni, SK, Choi, BD, Kuan, C-T, Suryadevara, CM, Snyder, DJ, Schmittling, RJ, Szafranski, SE, Cui, X, Healy, PN, Herndon, JE, McLendon, RE, Keir, ST, Archer, GE, Reap, EA, Sanchez-Perez, L, Bigner, DD, and Sampson, JH. "A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 24, no. 15 (August 2018): 3611-3631. Full Text
  - Keir, ST, Chandramohan, V, Hemphill, CD, Grandal, MM, Melander, MC, Pedersen, MW, Horak, ID, Kragh, M, Desjardins, A, Friedman, HS, and Bigner, DD. "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models." Journal of Neuro Oncology 138, no. 3 (July 2018): 489-498. Full Text
  - Mack, SC, Pajtler, KW, Chavez, L, Okonechnikov, K, Bertrand, KC, Wang, X, Erkek, S, Federation, A, Song, A, Lee, C, Wang, X, McDonald, L, Morrow, JJ, Saiakhova, A, Sin-Chan, P, Wu, Q, Michaelraj, KA, Miller, TE, Hubert, CG, Ryzhova, M, Garzia, L, Donovan, L, Dombrowski, S, Factor, DC, Luu, B, Valentim, CLL, Gimple, RC, Morton, A, Kim, L, Prager, BC, Lee, JJY, Wu, X, Zuccaro, J, Thompson, Y, Holgado, BL, Reimand, J, Ke, SQ, Tropper, A, Lai, S, Vijayarajah, S, Doan, S, Mahadev, V, Miñan, AF, Gröbner, SN, Lienhard, M, Zapatka, M, Huang, Z, Aldape, KD, Carcaboso, AM, Houghton, PJ, Keir, ST, Milde, T, Witt, H, Li, Y, Li, C-J, Bian, X-W, Jones, DTW, Scott, I, Singh, SK, Huang, A, Dirks, PB, Bouffet, E, Bradner, JE, Ramaswamy, V, Jabado, N, Rutka, JT, Northcott, PA, Lupien, M, Lichter, P, Korshunov, A, Scacheri, PC, Pfister, SM, Kool, M, Taylor, MD, and Rich, JN. "Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling." Nature 553, no. 7686 (January 2018): 101-105. Full Text
  - Chandramohan, V, Bryant, JD, Piao, H, Keir, ST, Lipp, ES, Lefaivre, M, Perkinson, K, Bigner, DD, Gromeier, M, and McLendon, RE. "Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas." Archives of pathology & laboratory medicine 141, no. 12 (December 2017): 1697-1704. Full Text
  - Randazzo, DM, McSherry, F, Herndon, JE, Affronti, ML, Lipp, ES, Flahiff, C, Miller, E, Woodring, S, Freeman, M, Healy, P, Minchew, J, Boulton, S, Desjardins, A, Vlahovic, G, Friedman, HS, Keir, S, and Peters, KB. "A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population." Journal of Neuro Oncology 134, no. 2 (September 2017): 363-369. Full Text
  - Thompson, EM, Keir, ST, Venkatraman, T, Lascola, C, Yeom, KW, Nixon, AB, Liu, Y, Picard, D, Remke, M, Bigner, DD, Ramaswamy, V, and Taylor, MD. "The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival." Neuro Oncology 19, no. 9 (September 2017): 1217-1227. Full Text
  - Kurmasheva, RT, Gorlick, R, Kolb, EA, Keir, ST, Maris, JM, Lock, RB, Carol, H, Kang, M, Reynolds, CP, Wu, J, Houghton, PJ, and Smith, MA. "Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 64, no. 4 (April 2017). Full Text
  - Lock, R, Carol, H, Maris, JM, Kolb, EA, Gorlick, R, Reynolds, CP, Kang, MH, Keir, ST, Wu, J, Purmal, A, Gudkov, A, Kurmashev, D, Kurmasheva, RT, Houghton, PJ, and Smith, MA. "Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program." Pediatric Blood & Cancer 64, no. 4 (April 2017). Full Text
  - Kang, MH, Reynolds, CP, Kolb, EA, Gorlick, R, Carol, H, Lock, R, Keir, ST, Maris, JM, Wu, J, Lyalin, D, Kurmasheva, RT, Houghton, PJ, and Smith, MA. "Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 63, no. 10 (October 2016): 1744-1752. Full Text
  - Murphy, B, Yin, H, Maris, JM, Kolb, EA, Gorlick, R, Reynolds, CP, Kang, MH, Keir, ST, Kurmasheva, RT, Dvorchik, I, Wu, J, Billups, CA, Boateng, N, Smith, MA, Lock, RB, and Houghton, PJ. "Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis." Cancer Research 76, no. 19 (October 2016): 5798-5809. Full Text
  - Bushey, RT, Moody, MA, Nicely, NL, Haynes, BF, Alam, SM, Keir, ST, Bentley, RC, Roy Choudhury, K, Gottlin, EB, Campa, MJ, Liao, H-X, and Patz, EF. "A Therapeutic Antibody for Cancer, Derived from Single Human B Cells." Cell reports 15, no. 7 (May 4, 2016): 1505-1513. Full Text Open Access Copy
  - Gorlick, R, Kolb, EA, Keir, ST, Maris, JM, Lock, RB, Carol, H, Reynolds, CP, Kang, MH, Billups, CA, Collins, J, Kurmashev, D, Kurmasheva, RT, Houghton, PJ, and Smith, MA. "Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 63, no. 3 (March 2016): 443-450. Full Text
  - Attiyeh, EF, Maris, JM, Lock, R, Reynolds, CP, Kang, MH, Carol, H, Gorlick, R, Kolb, EA, Keir, ST, Wu, J, Landesman, Y, Shacham, S, Lyalin, D, Kurmasheva, RT, Houghton, PJ, and Smith, MA. "Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program." Pediatric Blood & Cancer 63, no. 2 (February 2016): 276-286. Full Text
  - Hu, J, Sun, T, Wang, H, Chen, Z, Wang, S, Yuan, L, Liu, T, Li, H-R, Wang, P, Feng, Y, Wang, Q, McLendon, RE, Friedman, AH, Keir, ST, Bigner, DD, Rathmell, J, Fu, X-D, Li, Q-J, Wang, H, and Wang, X-F. "MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B." Cancer Cell 29, no. 1 (January 2016): 49-60. Full Text Open Access Copy
  - Okamura, T, Antoun, G, Keir, ST, Friedman, H, Bigner, DD, and Ali-Osman, F. "Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells." The Journal of biological chemistry 290, no. 52 (December 2015): 30866-30878. Full Text
  - Brown, KE, Chagoya, G, Kwatra, SG, Yen, T, Keir, ST, Cooter, M, Hoadley, KA, Rasheed, A, Lipp, ES, Mclendon, R, Ali-Osman, F, Bigner, DD, Sampson, JH, and Kwatra, MM. "Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development." Journal of Neurochemistry 133, no. 5 (June 2015): 730-738. Full Text
  - Choudhury, KR, Keir, ST, Ashcraft, KA, Boss, M-K, and Dewhirst, MW. "Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies." Oncotarget 6, no. 16 (June 2015): 14656-14668. Full Text
  - Kolb, EA, Gorlick, R, Keir, ST, Maris, JM, Kang, MH, Reynolds, CP, Lock, RB, Carol, H, Wu, J, Kurmasheva, RT, Houghton, PJ, and Smith, MA. "Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program." Pediatric Blood & Cancer 62, no. 6 (June 2015): 1106-1109. Full Text
  - Smith, MA, Reynolds, CP, Kang, MH, Kolb, EA, Gorlick, R, Carol, H, Lock, RB, Keir, ST, Maris, JM, Billups, CA, Lyalin, D, Kurmasheva, RT, and Houghton, PJ. "Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 21, no. 4 (February 2015): 819-832. Full Text
  - Brown, KE, Chagoya, G, Kwatra, SG, Yen, T, Keir, ST, Cooter, M, Hoadley, KA, Rasheed, A, Lipp, ES, McLendon, R, Ali-Osman, F, Bigner, DD, Sampson, JH, and Kwatra, MM. "Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: Implications for drug development." Journal of Neurochemistry 133, no. 5 (2015): 730-738. Full Text
  - Smith, MA, Hampton, OA, Reynolds, CP, Kang, MH, Maris, JM, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Keir, ST, Wu, J, Kurmasheva, RT, Wheeler, DA, and Houghton, PJ. "Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673." Pediatric Blood & Cancer 62, no. 1 (January 2015): 91-98. Full Text
  - Di, K, Keir, ST, Alexandru-Abrams, D, Gong, X, Nguyen, H, Friedman, HS, and Bota, DA. "Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models." Journal of neuro-oncology 120, no. 3 (December 2014): 473-481. Full Text
  - Houghton, PJ, Kurmasheva, RT, Lyalin, D, Maris, JM, Kolb, EA, Gorlick, R, Reynolds, CP, Kang, MH, Keir, ST, Wu, J, and Smith, MA. "Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program." Pediatric Blood & Cancer 61, no. 11 (November 2014): 1972-1979. Full Text
  - Wang, H, Sun, T, Hu, J, Zhang, R, Rao, Y, Wang, S, Chen, R, McLendon, RE, Friedman, AH, Keir, ST, Bigner, DD, Li, Q-J, Wang, H, and Wang, X-F. "miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways." The Journal of Clinical Investigation 124, no. 10 (October 2014): 4489-4502. Full Text
  - Carol, H, Maris, JM, Kang, MH, Reynolds, CP, Kolb, EA, Gorlick, R, Keir, ST, Wu, J, Lyalin, D, Kurmasheva, RT, Houghton, PJ, Smith, MA, and Lock, RB. "Initial Testing (Stage 1) of the Notch Inhibitor PF-03084014, by the Pediatric Preclinical Testing Program (vol 61, pg 1493, 2014)." PEDIATRIC BLOOD & CANCER 61, no. 9 (September 2014): 1716-1716. Full Text Link to Item
  - Carol, H, Maris, JM, Kang, MH, Reynolds, CP, Kolb, EA, Gorlick, R, Keir, ST, Wu, J, Kurmasheva, RT, Houghton, PJ, Smith, MA, Lock, RB, and Lyalin, D. "Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program." Pediatric Blood & Cancer 61, no. 8 (August 2014): 1493-1496. Full Text
  - Kang, MH, Reynolds, CP, Maris, JM, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Keir, ST, Wu, J, Lyalin, D, Kurmasheva, RT, Houghton, PJ, and Smith, MA. "Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program." Pediatric Blood & Cancer 61, no. 8 (August 2014): 1486-1489. Full Text
  - Killela, PJ, Pirozzi, CJ, Healy, P, Reitman, ZJ, Lipp, E, Rasheed, BA, Yang, R, Diplas, BH, Wang, Z, Greer, PK, Zhu, H, Wang, CY, Carpenter, AB, Friedman, H, Friedman, AH, Keir, ST, He, J, He, Y, McLendon, RE, Herndon, JE, Yan, H, and Bigner, DD. "Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas." Oncotarget 5, no. 6 (March 2014): 1515-1525. Full Text Open Access Copy
  - Carol, H, Gorlick, R, Kolb, EA, Morton, CL, Manesh, DM, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Wozniak, A, Hickson, I, Lyalin, D, Kurmasheva, RT, Houghton, PJ, Smith, MA, and Lock, R. "Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program." Pediatric Blood and Cancer 61, no. 2 (February 1, 2014): 245-252. Full Text
  - Carol, H, Gorlick, R, Kolb, EA, Morton, CL, Manesh, DM, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Wozniak, A, Hickson, I, Lyalin, D, Kurmasheva, RT, Houghton, PJ, Smith, MA, and Lock, R. "Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 61, no. 2 (February 2014): 245-252. Full Text
  - Gorlick, R, Kolb, EA, Keir, ST, Maris, JM, Reynolds, CP, Kang, MH, Carol, H, Lock, R, Billups, CA, Kurmasheva, RT, Houghton, PJ, and Smith, MA. "Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 61, no. 1 (January 2014): 158-164. Full Text
  - Guo, C, Chen, LH, Huang, Y, Chang, C-C, Wang, P, Pirozzi, CJ, Qin, X, Bao, X, Greer, PK, McLendon, RE, Yan, H, Keir, ST, Bigner, DD, and He, Y. "KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation." Oncotarget 4, no. 11 (November 2013): 2144-2153. Full Text
  - Wood, AC, Maris, JM, Gorlick, R, Kolb, EA, Keir, ST, Reynolds, CP, Kang, MH, Wu, J, Kurmasheva, RT, Whiteman, K, Houghton, PJ, and Smith, MA. "Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program." Pediatric Blood & Cancer 60, no. 11 (November 2013): 1860-1867. Full Text
  - Frattini, V, Trifonov, V, Chan, JM, Castano, A, Lia, M, Abate, F, Keir, ST, Ji, AX, Zoppoli, P, Niola, F, Danussi, C, Dolgalev, I, Porrati, P, Pellegatta, S, Heguy, A, Gupta, G, Pisapia, DJ, Canoll, P, Bruce, JN, McLendon, RE, Yan, H, Aldape, K, Finocchiaro, G, Mikkelsen, T, Privé, GG, Bigner, DD, Lasorella, A, Rabadan, R, and Iavarone, A. "The integrated landscape of driver genomic alterations in glioblastoma." Nature Genetics 45, no. 10 (October 2013): 1141-1149. Full Text
  - Chandramohan, V, Bao, X, Keir, ST, Pegram, CN, Szafranski, SE, Piao, H, Wikstrand, CJ, McLendon, RE, Kuan, C-T, Pastan, IH, and Bigner, DD. "Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 19, no. 17 (September 2013): 4717-4727. Full Text
  - Piao, H, Kuan, C-T, Chandramohan, V, Keir, ST, Pegram, CN, Bao, X, Månsson, J-E, Pastan, IH, and Bigner, DD. "Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas." MAbs 5, no. 5 (September 2013): 748-762. Full Text Link to Item
  - Kolb, EA, Gorlick, R, Reynolds, CP, Kang, MH, Carol, H, Lock, R, Keir, ST, Maris, JM, Billups, CA, Desjardins, C, Kurmasheva, RT, Houghton, PJ, and Smith, MA. "Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program." Pediatric Blood & Cancer 60, no. 8 (August 2013): 1325-1332. Full Text
  - Lock, RB, Carol, H, Maris, JM, Kang, MH, Reynolds, CP, Kolb, EA, Gorlick, R, Keir, ST, Billups, CA, Kurmasheva, RT, Houghton, PJ, and Smith, MA. "Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 60, no. 7 (July 2013): E42-E45. Full Text
  - Chandramohan, V, Bao, X, Kato Kaneko, M, Kato, Y, Keir, ST, Szafranski, SE, Kuan, C-T, Pastan, IH, and Bigner, DD. "Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors." Int J Cancer 132, no. 10 (May 15, 2013): 2339-2348. Full Text Link to Item
  - Keir, ST, Maris, JM, Reynolds, CP, Kang, MH, Kolb, EA, Gorlick, R, Lock, R, Carol, H, Morton, CL, Wu, J, Kurmasheva, RT, Houghton, PJ, and Smith, MA. "Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program." Pediatric Blood & Cancer 60, no. 5 (May 2013): 783-790. Full Text
  - Reynolds, CP, Kang, MH, Carol, H, Lock, R, Gorlick, R, Kolb, EA, Kurmasheva, RT, Keir, ST, Maris, JM, Billups, CA, Houghton, PJ, and Smith, MA. "Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program." Pediatric Blood & Cancer 60, no. 5 (May 2013): 791-798. Full Text
  - Bettegowda, C, Agrawal, N, Jiao, Y, Wang, Y, Wood, LD, Rodriguez, FJ, Hruban, RH, Gallia, GL, Binder, ZA, Riggins, CJ, Salmasi, V, Riggins, GJ, Reitman, ZJ, Rasheed, A, Keir, S, Shinjo, S, Marie, S, McLendon, R, Jallo, G, Vogelstein, B, Bigner, D, Yan, H, Kinzler, KW, and Papadopoulos, N. "Exomic Sequencing of Four Rare Central Nervous System Tumor Types." ONCOTARGET 4, no. 4 (April 2013): 572-583. Full Text Link to Item
  - Carol, H, Reynolds, CP, Kang, MH, Keir, ST, Maris, JM, Gorlick, R, Kolb, EA, Billups, CA, Geier, B, Kurmasheva, RT, Houghton, PJ, Smith, MA, and Lock, RB. "Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 60, no. 4 (April 2013): 633-641. Full Text
  - Poteet, E, Choudhury, GR, Winters, A, Li, W, Ryou, M-G, Liu, R, Tang, L, Ghorpade, A, Wen, Y, Yuan, F, Keir, ST, Yan, H, Bigner, DD, Simpkins, JW, and Yang, S-H. "Reversing the Warburg effect as a treatment for glioblastoma." The Journal of Biological Chemistry 288, no. 13 (March 2013): 9153-9164. Full Text
  - Chandramohan, V, Bao, X, Kaneko, MK, Kato, Y, Keir, ST, Szafranski, SE, Kuan, C-T, Pastan, IH, and Bigner, DD. "Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors." International Journal of Cancer 132, no. 10 (2013): 2339-2348. Full Text
  - Frattini, V, Trifonov, V, Chan, JM, Castano, A, Lia, M, Abate, F, Keir, ST, Ji, AX, Zoppoli, P, Niola, F, and al, E. "The integrated landscape of driver genomic alterations in glioblastoma." Nature Genetics 45, no. 10 (2013): 1141-1149. Full Text
  - Keir, ST, Friedman, HS, Reardon, DA, Bigner, DD, and Gray, LA. "Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model." Journal of Neuro Oncology 111, no. 2 (January 2013): 97-102. Full Text
  - Keir, ST, Friedman, HS, Reardon, DA, Bigner, DD, and Gray, LA. "Mibefradil, a novel therapy for glioblastoma multiforme: Cell cycle synchronization and interlaced therapy in a murine model." Journal of Neuro-Oncology 111, no. 2 (2013): 97-102. Full Text
  - Gorlick, R, Kolb, EA, Houghton, PJ, Morton, CL, Neale, G, Keir, ST, Carol, H, Lock, R, Phelps, D, Kang, MH, Reynolds, CP, Maris, JM, Billups, C, and Smith, MA. "Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program." Pediatric Blood & Cancer 59, no. 7 (December 2012): 1266-1274. Full Text
  - Keir, ST, and Saling, JR. "Pilot study of the impact of massage therapy on sources and levels of distress in brain tumour patients." BMJ supportive & palliative care 2, no. 4 (December 2012): 363-366. Full Text
  - Gurley, SN, Abidi, AH, Allison, P, Guan, P, Duntsch, C, Robertson, JH, Kosanke, SD, Keir, ST, Bigner, DD, Elberger, AJ, and Moore, BM. "Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233." J Neurooncol 110, no. 2 (November 2012): 163-177. Full Text Link to Item
  - Batra, V, Maris, JM, Kang, MH, Reynolds, CP, Houghton, PJ, Alexander, D, Kolb, EA, Gorlick, R, Keir, ST, Carol, H, Lock, R, Billups, CA, and Smith, MA. "Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program." Pediatr Blood Cancer 59, no. 4 (October 2012): 749-752. Full Text Link to Item
  - Gorlick, R, Maris, JM, Houghton, PJ, Lock, R, Carol, H, Kurmasheva, RT, Kolb, EA, Keir, ST, Reynolds, CP, Kang, MH, Billups, CA, and Smith, MA. "Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 59, no. 3 (September 2012): 518-524. Full Text
  - Keir, ST, Morton, CL, Wu, J, Kurmasheva, RT, Houghton, PJ, and Smith, MA. "Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 59, no. 3 (September 2012): 586-588. Full Text
  - Smith, MA, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Maris, JM, Keir, ST, Morton, CL, Reynolds, CP, Kang, MH, Arts, J, Bashir, T, Janicot, M, Kurmasheva, RT, and Houghton, PJ. "Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program." Pediatric Blood & Cancer 59, no. 2 (August 2012): 329-332. Full Text
  - Smith, MA, Maris, JM, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Keir, ST, Reynolds, CP, Kang, MH, Morton, CL, Wu, J, Smith, PG, Yu, J, and Houghton, PJ. "Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program." Pediatric Blood & Cancer 59, no. 2 (August 2012): 246-253. Full Text
  - Kang, MH, Reynolds, CP, Houghton, PJ, Alexander, D, Morton, CL, Kolb, EA, Gorlick, R, Keir, ST, Carol, H, Lock, R, Maris, JM, Wozniak, A, and Smith, MA. "Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program." Pediatric Blood & Cancer 59, no. 1 (July 2012): 185-188. Full Text
  - Lock, RB, Carol, H, Morton, CL, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Wozniak, AW, Gorlick, R, Kolb, EA, Houghton, PJ, and Smith, MA. "Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program." Pediatric Blood & Cancer 58, no. 6 (June 2012): 916-923. Full Text
  - Kolb, EA, Gorlick, R, Keir, ST, Maris, JM, Lock, R, Carol, H, Kurmasheva, RT, Reynolds, CP, Kang, MH, Wu, J, Houghton, PJ, and Smith, MA. "Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling." Pediatric Blood & Cancer 58, no. 5 (May 2012): 815-818. Full Text
  - Kolb, EA, Gorlick, R, Maris, JM, Keir, ST, Morton, CL, Wu, J, Wozniak, AW, Smith, MA, and Houghton, PJ. "Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program." Pediatric Blood & Cancer 58, no. 5 (May 2012): 729-735. Full Text
  - Houghton, PJ, Kang, MH, Reynolds, CP, Morton, CL, Kolb, EA, Gorlick, R, Keir, ST, Carol, H, Lock, R, Maris, JM, Billups, CA, and Smith, MA. "Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 58, no. 4 (April 2012): 636-639. Full Text
  - Morton, CL, Maris, JM, Keir, ST, Gorlick, R, Kolb, EA, Billups, CA, Wu, J, Smith, MA, and Houghton, PJ. "Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program." Pediatric Blood & Cancer 58, no. 4 (April 2012): 566-571. Full Text
  - Houghton, PJ, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Morton, CL, Keir, ST, Reynolds, CP, Kang, MH, Phelps, D, Maris, JM, Billups, C, and Smith, MA. "Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program." Pediatric Blood & Cancer 58, no. 2 (February 2012): 191-199. Full Text
  - Houghton, PJ, Lock, R, Carol, H, Morton, CL, Gorlick, R, Anders Kolb, E, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Billups, CA, Zhang, MX, Madden, SL, Teicher, BA, and Smith, MA. "Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program." Pediatric Blood & Cancer 58, no. 2 (February 2012): 200-209. Full Text
  - Morton, CL, Houghton, PJ, Kolb, EA, Gorlick, R, Reynolds, CP, Kang, MH, Maris, JM, Keir, ST, Wu, J, and Smith, MA. "Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program." Pediatric Blood and Cancer 58, no. 4 (2012): 652--. Full Text
  - Smith, MA, Maris, JM, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Keir, ST, Reynolds, CP, Kang, MH, Morton, CL, Wu, J, Smith, PG, Yu, J, and Houghton, PJ. "Malcolm A. Smith, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Christopher L. Morton, Jianrong Wu, Peter G. Smith, Jie Yu and Peter J. Houghton. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Aug.; 59(2):246-253." Pediatric Blood and Cancer 59, no. 4 (2012): 772-772. Full Text
  - Carol, H, Boehm, I, Reynolds, CP, Kang, MH, Maris, JM, Morton, CL, Gorlick, R, Kolb, EA, Keir, ST, Wu, J, Wozniak, AE, Yang, Y, Manfredi, M, Ecsedy, J, Wang, J, Neale, G, Houghton, PJ, Smith, MA, and Lock, RB. "Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer." Cancer Chemotherapy and Pharmacology 68, no. 5 (November 2011): 1291-1304. Full Text
  - Reynolds, CP, Kang, MH, Keir, ST, Gorlick, R, Kolb, EA, Lock, R, Maris, JM, Carol, H, Morton, CL, Billups, CA, Smith, MA, and Houghton, PJ. "Initial testing of lenalidomide by the pediatric preclinical testing program." Pediatric Blood & Cancer 57, no. 4 (October 2011): 606-611. Full Text
  - Houghton, PJ, Lock, R, Carol, H, Morton, CL, Phelps, D, Gorlick, R, Kolb, EA, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Wozniak, AW, Gu, Y, Wilson, WR, and Smith, MA. "Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program." Pediatric Blood & Cancer 57, no. 3 (September 2011): 443-453. Full Text
  - Smith, MA, Maris, JM, Lock, R, Kolb, EA, Gorlick, R, Keir, ST, Carol, H, Morton, CL, Reynolds, CP, Kang, MH, and Houghton, PJ. "Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program." Pediatric Blood & Cancer 57, no. 2 (August 2011): 268-274. Full Text
  - Kuan, C-T, Wakiya, K, Keir, ST, Li, J, Herndon, JE, Pastan, I, and Bigner, DD. "Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas." Int J Cancer 129, no. 1 (July 1, 2011): 111-121. Full Text Link to Item
  - Keir, ST. "Effect of massage therapy on stress levels and quality of life in brain tumor patients--observations from a pilot study." Support Care Cancer 19, no. 5 (May 2011): 711-715. Full Text Link to Item
  - Kolb, EA, Gorlick, R, Lock, R, Carol, H, Morton, CL, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Billups, C, Smith, MA, and Houghton, PJ. "Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program." Pediatric Blood & Cancer 56, no. 4 (April 2011): 595-603. Full Text
  - Keir, ST, Dewhirst, MW, Kirkpatrick, JP, Bigner, DD, and Batinic-Haberle, I. "Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors." Anticancer Agents Med Chem 11, no. 2 (February 2011): 202-212. Link to Item
  - Parsons, DW, Li, M, Zhang, X, Jones, S, Leary, RJ, Lin, JC-H, Boca, SM, Carter, H, Samayoa, J, Bettegowda, C, Gallia, GL, Jallo, GI, Binder, ZA, Nikolsky, Y, Hartigan, J, Smith, DR, Gerhard, DS, Fults, DW, VandenBerg, S, Berger, MS, Marie, SKN, Shinjo, SMO, Clara, C, Phillips, PC, Minturn, JE, Biegel, JA, Judkins, AR, Resnick, AC, Storm, PB, Curran, T, He, Y, Rasheed, BA, Friedman, HS, Keir, ST, McLendon, R, Northcott, PA, Taylor, MD, Burger, PC, Riggins, GJ, Karchin, R, Parmigiani, G, Bigner, DD, Yan, H, Papadopoulos, N, Vogelstein, B, Kinzler, KW, and Velculescu, VE. "The genetic landscape of the childhood cancer medulloblastoma." Science (New York, N.Y.) 331, no. 6016 (January 2011): 435-439. Full Text
  - Carol, H, Morton, CL, Gorlick, R, Kolb, EA, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Billups, C, Smith, MA, Houghton, PJ, and Lock, RB. "Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program." Pediatric Blood & Cancer 55, no. 7 (December 2010): 1329-1337. Full Text
  - Gamez, I, Ryan, RP, and Keir, ST. "Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models." Anticancer Res 30, no. 12 (December 2010): 5037-5042. Link to Item
  - Keir, ST, Maris, JM, Lock, R, Kolb, EA, Gorlick, R, Carol, H, Morton, CL, Reynolds, CP, Kang, MH, Watkins, A, Houghton, PJ, and Smith, MA. "Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program." Pediatric Blood & Cancer 55, no. 6 (December 2010): 1126-1133. Full Text
  - Kato, Y, Vaidyanathan, G, Kaneko, MK, Mishima, K, Srivastava, N, Chandramohan, V, Pegram, C, Keir, ST, Kuan, C-T, Bigner, DD, and Zalutsky, MR. "Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas." Nucl Med Biol 37, no. 7 (October 2010): 785-794. Full Text Link to Item
  - Kolb, EA, Gorlick, R, Houghton, PJ, Morton, CL, Neale, G, Keir, ST, Carol, H, Lock, R, Phelps, D, Kang, MH, Reynolds, CP, Maris, JM, Billups, C, and Smith, MA. "Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 55, no. 4 (October 2010): 668-677. Full Text
  - Jin, G, Cook, S, Cui, B, Chen, WC, Keir, ST, Killela, P, Di, C, Payne, CA, Gregory, SG, McLendon, R, Bigner, DD, and Yan, H. "HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea." Neuro Oncol 12, no. 9 (September 2010): 956-966. Full Text Link to Item
  - Morton, CL, Houghton, PJ, Kolb, EA, Gorlick, R, Reynolds, CP, Kang, MH, Maris, JM, Keir, ST, Wu, J, and Smith, MA. "Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program." Pediatric Blood & Cancer 55, no. 2 (August 2010): 295-303. Full Text
  - Zhu, H, Cao, X, Ali-Osman, F, Keir, S, and Lo, H-W. "EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity." Cancer Lett 294, no. 1 (August 1, 2010): 101-110. Full Text Link to Item
  - Vaidyanathan, G, Affleck, DJ, Zhao, XG, Keir, ST, and Zalutsky, MR. "[¹⁷⁷Lu]-DOTA⁰-Tyr³-octreotate: A potential targeted radiotherapeutic for the treatment of Medulloblastoma." Current Radiopharmaceuticals 3, no. 1 (July 12, 2010): 29-36. Full Text
  - Houghton, PJ, Morton, CL, Gorlick, R, Kolb, EA, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Wu, J, and Smith, MA. "Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program." Pediatric Blood & Cancer 54, no. 7 (July 2010): 921-926. Full Text
  - Maris, JM, Morton, CL, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Keir, ST, Reynolds, CP, Kang, MH, Wu, J, Smith, MA, and Houghton, PJ. "Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)." Pediatric Blood & Cancer 55, no. 1 (July 2010): 26-34. Full Text
  - Carol, H, Houghton, PJ, Morton, CL, Kolb, EA, Gorlick, R, Reynolds, CP, Kang, MH, Maris, JM, Keir, ST, Watkins, A, Smith, MA, and Lock, RB. "Initial testing of topotecan by the pediatric preclinical testing program." Pediatric Blood & Cancer 54, no. 5 (May 2010): 707-715. Full Text
  - Jones, LW, Viglianti, BL, Tashjian, JA, Kothadia, SM, Keir, ST, Freedland, SJ, Potter, MQ, Moon, EJ, Schroeder, T, Herndon, JE, and Dewhirst, MW. "Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer." Journal of Applied Physiology (Bethesda, Md. : 1985) 108, no. 2 (February 2010): 343-348. Full Text
  - Smith, MA, Morton, CL, Kolb, EA, Gorlick, R, Keir, ST, Carol, H, Lock, R, Kang, MH, Reynolds, CP, Maris, JM, Watkins, AE, and Houghton, PJ. "Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program." Pediatric Blood & Cancer 54, no. 2 (February 2010): 307-310. Full Text
  - Houghton, PJ, Morton, CL, Gorlick, R, Lock, RB, Carol, H, Reynolds, CP, Kang, MH, Maris, JM, Keir, ST, Kolb, EA, Wu, J, Wozniak, AW, Billups, CA, Rubinstein, L, and Smith, MA. "Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program." Molecular Cancer Therapeutics 9, no. 1 (January 6, 2010): 101-112. Full Text
  - Jones, LW, Viglianti, BL, Tashjian, JA, Kothadia, SM, Keir, ST, Freedland, SJ, Potter, MQ, Moon, EJ, Schroeder, T, Herndon, JE, and Dewhirst, MW. "Erratum: Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer (Journal of Applied Physiology (2010) 108: (343-348) DOI: 10.1152/japplphysiol.00424.2009)." Journal of Applied Physiology 108, no. 4 (2010): 1021--. Full Text
  - Vaidyanathan, G, Affleck, DJ, Zhao, X-G, Keir, ST, and Zalutsky, MR. "[Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma." Curr Radiopharm 3, no. 1 (2010): 29-36. Full Text Link to Item
  - Carol, H, Lock, R, Houghton, PJ, Morton, CL, Kolb, EA, Gorlick, R, Reynolds, CP, Maris, JM, Keir, ST, Billups, CA, and Smith, MA. "Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program." Pediatric Blood & Cancer 53, no. 7 (December 2009): 1255-1263. Full Text
  - Gorlick, R, Kolb, EA, Houghton, PJ, Morton, CL, Phelps, D, Schaiquevich, P, Stewart, C, Keir, ST, Lock, R, Carol, H, Reynolds, CP, Maris, JM, Wu, J, and Smith, MA. "Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program." Pediatric Blood & Cancer 53, no. 4 (October 2009): 594-598. Full Text
  - Keshelava, N, Houghton, PJ, Morton, CL, Lock, RB, Carol, H, Keir, ST, Maris, JM, Reynolds, CP, Gorlick, R, Kolb, EA, Wu, J, and Smith, MA. "Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program." Pediatric Blood & Cancer 53, no. 3 (September 2009): 505-508. Full Text
  - Morton, CL, Houghton, PJ, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Billups, C, and Smith, MA. "Initial testing of aplidin by the pediatric pre-clinical testing program." Pediatric Blood & Cancer 53, no. 3 (September 2009): 509-512. Full Text
  - Keir, ST, Farland, MM, Lipp, ES, and Friedman, HS. "Family appraisal of caregiving in a brain cancer model." Journal of Hospice and Palliative Nursing 11, no. 1 (2009): 60-66. Full Text
  - Keir, ST, Farland, MM, Lipp, ES, and Friedman, HS. "Distress persists in long-term brain tumor survivors with glioblastoma multiforme." J Cancer Surviv 2, no. 4 (December 2008): 269-274. Full Text Link to Item
  - Parsons, DW, Jones, S, Zhang, X, Lin, JC-H, Leary, RJ, Angenendt, P, Mankoo, P, Carter, H, Siu, I-M, Gallia, GL, Olivi, A, McLendon, R, Rasheed, BA, Keir, S, Nikolskaya, T, Nikolsky, Y, Busam, DA, Tekleab, H, Diaz, LA, Hartigan, J, Smith, DR, Strausberg, RL, Marie, SKN, Shinjo, SMO, Yan, H, Riggins, GJ, Bigner, DD, Karchin, R, Papadopoulos, N, Parmigiani, G, Vogelstein, B, Velculescu, VE, and Kinzler, KW. "An integrated genomic analysis of human glioblastoma multiforme." Science (New York, N.Y.) 321, no. 5897 (September 4, 2008): 1807-1812. Full Text
  - Keir, ST, Morton, CL, Billups, C, Smith, MA, Houghton, PJ, and Gururangan, S. "Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program." Pediatric Blood & Cancer 51, no. 3 (September 2008): 439-441. Full Text
  - Maris, JM, Courtright, J, Houghton, PJ, Morton, CL, Kolb, EA, Lock, R, Tajbakhsh, M, Reynolds, CP, Keir, ST, Wu, J, and Smith, MA. "Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program." Pediatric Blood & Cancer 51, no. 1 (July 2008): 42-48. Full Text
  - Smith, MA, Morton, CL, Phelps, DA, Kolb, EA, Lock, R, Carol, H, Reynolds, CP, Maris, JM, Keir, ST, Wu, J, and Houghton, PJ. "Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program." Pediatric Blood & Cancer 51, no. 1 (July 2008): 34-41. Full Text
  - Keir, ST, Calhoun-Eagan, RD, Swartz, JJ, Saleh, OA, and Friedman, HS. "Screening for distress in patients with brain cancer using the NCCN's rapid screening measure." Psychooncology 17, no. 6 (June 2008): 621-625. Full Text Link to Item
  - Kolb, EA, Gorlick, R, Houghton, PJ, Morton, CL, Lock, R, Carol, H, Reynolds, CP, Maris, JM, Keir, ST, Billups, CA, and Smith, MA. "Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program." Pediatric Blood & Cancer 50, no. 6 (June 2008): 1190-1197. Full Text
  - Kolb, EA, Gorlick, R, Houghton, PJ, Morton, CL, Lock, RB, Tajbakhsh, M, Reynolds, CP, Maris, JM, Keir, ST, Billups, CA, and Smith, MA. "Initial testing of dasatinib by the pediatric preclinical testing program." Pediatric Blood & Cancer 50, no. 6 (June 2008): 1198-1206. Full Text
  - Lock, R, Carol, H, Houghton, PJ, Morton, CL, Kolb, EA, Gorlick, R, Reynolds, CP, Maris, JM, Keir, ST, Wu, J, and Smith, MA. "Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program." Pediatric Blood & Cancer 50, no. 6 (June 2008): 1181-1189. Full Text
  - Tajbakhsh, M, Houghton, PJ, Morton, CL, Kolb, EA, Gorlick, R, Maris, JM, Keir, ST, Wu, J, Reynolds, CP, Smith, MA, and Lock, RB. "Initial testing of cisplatin by the pediatric preclinical testing program." Pediatric Blood & Cancer 50, no. 5 (May 2008): 992-1000. Full Text
  - Houghton, PJ, Morton, CL, Kolb, EA, Gorlick, R, Lock, R, Carol, H, Reynolds, CP, Maris, JM, Keir, ST, Billups, CA, and Smith, MA. "Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program." Pediatric Blood & Cancer 50, no. 4 (April 2008): 799-805. Full Text
  - Maris, JM, Courtright, J, Houghton, PJ, Morton, CL, Gorlick, R, Kolb, EA, Lock, R, Tajbakhsh, M, Reynolds, CP, Keir, ST, Wu, J, and Smith, MA. "Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program." Pediatric Blood & Cancer 50, no. 3 (March 2008): 581-587. Full Text
  - Houghton, PJ, Morton, CL, Kolb, EA, Lock, R, Carol, H, Reynolds, CP, Keshelava, N, Maris, JM, Keir, ST, Wu, J, and Smith, MA. "Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program." Pediatric Blood & Cancer 50, no. 1 (January 2008): 37-45. Full Text
  - Houghton, PJ, Morton, CL, Tucker, C, Payne, D, Favours, E, Cole, C, Gorlick, R, Kolb, EA, Zhang, W, Lock, R, Carol, H, Tajbakhsh, M, Reynolds, CP, Maris, JM, Courtright, J, Keir, ST, Friedman, HS, Stopford, C, Zeidner, J, Wu, J, Liu, T, Billups, CA, Khan, J, Ansher, S, Zhang, J, and Smith, MA. "The pediatric preclinical testing program: description of models and early testing results." Pediatric Blood & Cancer 49, no. 7 (December 2007): 928-940. Full Text
  - Keir, ST, Swartz, JJ, and Friedman, HS. "Stress and long-term survivors of brain cancer." Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer 15, no. 12 (December 2007): 1423-1428. Full Text
  - Keir, ST. "Levels of stress and intervention preferences of caregivers of brain tumor patients." Cancer Nurs 30, no. 6 (November 2007): E33-E39. Full Text Link to Item
  - Swartz, JJ, and Keir, ST. "Program preferences to reduce stress in caregivers of patients with brain tumors." Clin J Oncol Nurs 11, no. 5 (October 2007): 723-727. Full Text Link to Item
  - Hjelmeland, AB, Lattimore, KP, Fee, BE, Shi, Q, Wickman, S, Keir, ST, Hjelmeland, MD, Batt, D, Bigner, DD, Friedman, HS, and Rich, JN. "The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion." Molecular Cancer Therapeutics 6, no. 9 (September 2007): 2449-2457. Full Text
  - Badruddoja, MA, Keir, ST, King, I, Zeidner, J, Vredenburgh, JJ, Muhlbaier, LH, Bigner, DD, and Friedman, HS. "Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice." Neuro Oncol 9, no. 3 (July 2007): 240-244. Full Text Link to Item
  - Shi, Q, Hjelmeland, AB, Keir, ST, Song, L, Wickman, S, Jackson, D, Ohmori, O, Bigner, DD, Friedman, HS, and Rich, JN. "A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth." Molecular Carcinogenesis 46, no. 6 (June 2007): 488-496. Full Text
  - Jones, LW, Guill, B, Keir, ST, Carter, K, Friedman, HS, Bigner, DD, and Reardon, DA. "Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer." Psychooncology 16, no. 3 (March 2007): 232-240. Full Text Link to Item
  - Jones, LW, Guill, B, Keir, ST, Carter, K, Friedman, HS, Bigner, DD, and Reardon, DA. "Exercise interest and preferences among patients diagnosed with primary brain cancer." Support Care Cancer 15, no. 1 (January 2007): 47-55. Full Text Link to Item
  - Keir, ST, Guill, AB, Carter, KE, Boole, LC, Gonzales, L, and Friedman, HS. "Differential levels of stress in caregivers of brain tumor patients--observations from a pilot study." Support Care Cancer 14, no. 12 (December 2006): 1258-1261. Full Text Link to Item
  - Keir, ST, Guill, AB, Carter, KE, and Friedman, HS. "Stress and intervention preferences of patients with brain tumors." Support Care Cancer 14, no. 12 (December 2006): 1213-1219. Full Text Link to Item
  - Sathornsumetee, S, Hjelmeland, AB, Keir, ST, McLendon, RE, Batt, D, Ramsey, T, Yusuff, N, Rasheed, BKA, Kieran, MW, Laforme, A, Bigner, DD, Friedman, HS, and Rich, JN. "AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma." Cancer Research 66, no. 17 (September 2006): 8722-8730. Full Text
  - Jones, LW, Guill, B, Keir, ST, Carter B S, K, Friedman, HS, Bigner, DD, and Reardon, DA. "Patterns of exercise across the cancer trajectory in brain tumor patients." Cancer 106, no. 10 (May 15, 2006): 2224-2232. Full Text Link to Item
  - Rich, JN, Sathornsumetee, S, Keir, ST, Kieran, MW, Laforme, A, Kaipainen, A, McLendon, RE, Graner, MW, Rasheed, BKA, Wang, L, Reardon, DA, Ryan, AJ, Wheeler, C, Dimery, I, Bigner, DD, and Friedman, HS. "ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors." Clin Cancer Res 11, no. 22 (November 15, 2005): 8145-8157. Full Text Link to Item
  - Cheng, CL, Johnson, SP, Keir, ST, Quinn, JA, Ali-Osman, F, Szabo, C, Li, H, Salzman, AL, Dolan, ME, Modrich, P, Bigner, DD, and Friedman, HS. "Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft." Mol Cancer Ther 4, no. 9 (September 2005): 1364-1368. Full Text Link to Item
  - Goudar, RK, Shi, Q, Hjelmeland, MD, Keir, ST, McLendon, RE, Wikstrand, CJ, Reese, ED, Conrad, CA, Traxler, P, Lane, HA, Reardon, DA, Cavenee, WK, Wang, X-F, Bigner, DD, Friedman, HS, and Rich, JN. "Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition." Molecular Cancer Therapeutics 4, no. 1 (January 2005): 101-112.
  - Friedman, HS, Keir, ST, and Houghton, PJ. "The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors." Cancer 97, no. 9 SUPPL. (May 1, 2003): 2359-2362.
  - Friedman, HS, Keir, S, Pegg, AE, Houghton, PJ, Colvin, OM, Moschel, RC, Bigner, DD, and Dolan, ME. "O6-benzylguanine-mediated enhancement of chemotherapy." Molecular Cancer Therapeutics 1, no. 11 (September 2002): 943-948.
  - Friedman, HS, Keir, ST, Houghton, PJ, Lawless, AA, Bigner, DD, and Waters, SJ. "Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice." Cancer Chemotherapy and Pharmacology 48, no. 5 (November 2001): 413-416. Full Text
  - Cavazos, CM, Keir, ST, Yoshinari, T, Bigner, DD, and Friedman, HS. "Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts." Cancer Chemotherapy and Pharmacology 48, no. 3 (September 2001): 250-254. Full Text
  - Keir, ST, Hausheer, F, Lawless, AA, Bigner, DD, and Friedman, HS. "Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice." Cancer Chemother Pharmacol 48, no. 1 (July 2001): 83-87. Link to Item
  - Struck, RF, Tiwari, A, Friedman, HS, Keir, S, Morgan, LR, and Waud, WR. "Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine." Cancer Chemother Pharmacol 48, no. 1 (July 2001): 47-52. Link to Item
  - Patel, VJ, Elion, GB, Houghton, PJ, Keir, S, Pegg, AE, Johnson, SP, Dolan, ME, Bigner, DD, and Friedman, HS. "Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 6, no. 10 (October 2000): 4154-4157.
  - Castellino, RC, Elion, GB, Keir, ST, Houghton, PJ, Johnson, SP, Bigner, DD, and Friedman, HS. "Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts." Cancer Chemotherapy and Pharmacology 45, no. 4 (January 2000): 345-349. Full Text
  - Friedman, HS, Castellino, RC, Elion, GB, Keir, ST, Houghton, PJ, Johnson, SP, and Bigner, DD. "Erratum: Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts (Cancer Chemotherapy and Pharmacology 45 (345- 349))." Cancer Chemotherapy and Pharmacology 46, no. 1 (2000): 84--.
  - Keir, ST, Dolan, ME, Pegg, AE, Lawless, A, Moschel, RC, Bigner, DD, and Friedman, HS. "O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials." Cancer Chemotherapy and Pharmacology 45, no. 6 (January 2000): 437-440. Full Text
  - Keir, ST, Dolan, ME, Pegg, AE, Lawless, A, Moschel, RC, Bigner, DD, and Friedman, HS. "O⁶-benzylguanine-mediated enhancement of nitrosourea activity in Mer^- central nervous system tumor xenografts - Implications for clinical trials." Cancer Chemotherapy and Pharmacology 45, no. 6 (2000): 437-440.
  - Friedman, HS, Pegg, AE, Johnson, SP, Loktionova, NA, Dolan, ME, Modrich, P, Moschel, RC, Struck, R, Brent, TP, Ludeman, S, Bullock, N, Kilborn, C, Keir, S, Dong, Q, Bigner, DD, and Colvin, OM. "Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase." Cancer Chemotherapy and Pharmacology 43, no. 1 (January 1999): 80-85. Full Text
  - Coggins, CA, Elion, GB, Houghton, PJ, Hare, CB, Keir, S, Colvin, OM, Bigner, DD, and Friedman, HS. "Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents." Cancer Chemotherapy and Pharmacology 41, no. 6 (January 1998): 485-490. Full Text
  - Hanley, ML, Elion, GB, Colvin, OM, Modrich, PL, Keir, S, Adams, DJ, Bigner, DD, and Friedman, HS. "Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors." Cancer Chemother Pharmacol 42, no. 6 (1998): 479-482. Link to Item
  - Friedman, HS, Johnson, SP, Dong, Q, Schold, SC, Rasheed, BK, Bigner, SH, Ali-Osman, F, Dolan, E, Colvin, OM, Houghton, P, Germain, G, Drummond, JT, Keir, S, Marcelli, S, Bigner, DD, and Modrich, P. "Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft." Cancer Research 57, no. 14 (July 1997): 2933-2936.
  - Hare, CB, Elion, GB, Colvin, OM, Ali-Osman, F, Griffith, OW, Petros, WP, Keir, S, Marcelli, SL, Bigner, DD, and Friedman, HS. "Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft." Cancer Chemother Pharmacol 40, no. 5 (1997): 409-414. Full Text Link to Item
  - Hare, CB, Elion, GB, Houghton, PJ, Houghton, JA, Keir, S, Marcelli, SL, Bigner, DD, and Friedman, HS. "Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts." Cancer Chemotherapy and Pharmacology 39, no. 3 (January 1997): 187-191. Full Text
  - Vaidyanathan, G, Friedman, HS, Keir, ST, and Zalutsky, MR. "Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model." Nucl Med Biol 23, no. 6 (August 1996): 851-856. Link to Item
  - Vaidyanathan, G, Friedman, HS, Keir, ST, and Zalutsky, MR. "Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity." Br J Cancer 73, no. 10 (May 1996): 1171-1177. Open Access Copy Link to Item
  - Moynihan, K, Elion, GB, Ali-Osman, F, Marcelli, S, Keir, S, Bigner, DD, and Friedman, HS. "Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta." Cancer Chemotherapy and Pharmacology 38, no. 4 (January 1996): 349-354. Full Text
  - Friedman, HS, Dolan, ME, Pegg, AE, Marcelli, S, Keir, S, Catino, JJ, Bigner, DD, and Schold, SC. "Activity of temozolomide in the treatment of central nervous system tumor xenografts." Cancer Research 55, no. 13 (July 1995): 2853-2857.
  - Aaron, RH, Elion, GB, Colvin, OM, Graham, M, Keir, S, Bigner, DD, and Friedman, HS. "Busulfan therapy of central nervous system xenografts in athymic mice." Cancer Chemotherapy and Pharmacology 35, no. 2 (January 1994): 127-131. Full Text
  - Friedman, HS, Houghton, PJ, Schold, SC, Keir, S, and Bigner, DD. "Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts." Cancer Chemotherapy and Pharmacology 34, no. 2 (January 1994): 171-174. Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

Selected Publications

Academic Articles